PIK3CA and hepatocellular carcinoma: To investigate whether the combination treatment is specific for PIK3CA mutant HCC, we tested the alpelisib/MLN0128 and alpelisib/palbociclib combination in SNU449 cells without transfection of PIK3CA mutations.